Generative Artificial Intelligence (AI) has quickly become a game-changer in clinical trials, revolutionizing how pharmaceutical companies, research institutions, and healthcare providers conduct their studies and create new treatments. This innovative approach utilizes machine learning algorithms and neural networks to produce data, predictions, and insights that can significantly increase the efficiency and effectiveness of clinical trials. In this comprehensive analysis, we will investigate the key influences governing the adoption and growth of generative AI in clinical trials, such as restraints, driving forces, opportunities, present trends, recent developments, future prospects, and regional considerations.
Global Generative AI in Clinical Trials industry size is expected to be worth around USD 1,122 million by 2032 from USD 140 million in 2022, growing at a CAGR of 23.8%. during the forecast period from 2023 to 2032.